Abstract
One of the neuropathological hallmarks of Alzheimer’s disease (AD) is the occurrence of neurofibrillary tangles (NFTs) that are composed of abnormally hyperphosphorylated microtubule-associated protein tau. Abnormal tau hyperphosphorylation is mainly induced due to the imbalance between protein kinases and phosphatases. In the tanglerich subregions of the hippocampus and parietal cortex in the brain of AD patients, the levels of the phosphorylationdependent protein peptidyl-prolyl cis-trans isomerase (Pin1) were found to be low. Although Pin1 can regulate tau phosphorylation, it is not clear whether the inhibition of glycogen synthase kinase 3 (GSK-3), the primary mediator of tau phosphorylation in AD, could reverse tau hyperphosphorylation induced due to the down-regulation of Pin1. We found that while suppression of Pin1, either by using its inhibitor Juglone or a shRNA plasmid against Pin1, induces tau hyperphosphorylation and GSK-3β activation both in vivo and in vitro, inhibition of GSK-3β by SB216763 or LiCl reverses tau hyperphosphorylation. Our data suggest that GSK-3β activation plays an important role in tau hyperphosphorylation induced by the down-regulation of Pin1, and the inhibition of GSK-3β might be a potential therapeutic approach for AD pathology.
Keywords: Alzheimer’s disease, GSK-3β, phosphorylation, Pin1, SB216763, shRNA, tau.
CNS & Neurological Disorders - Drug Targets
Title:Inhibition of Glycogen Synthase Kinase-3 Reverses Tau Hyperphosphorylation Induced by Pin1 Down-Regulation
Volume: 12 Issue: 3
Author(s): Yan-Si Xiong, Dan-Li Wang, Lu Tan, Xiong Wang, Li-Ming Chen, Cheng-Xin Gong, Jian-Zhi Wang and Ling-Qiang Zhu
Affiliation:
Keywords: Alzheimer’s disease, GSK-3β, phosphorylation, Pin1, SB216763, shRNA, tau.
Abstract: One of the neuropathological hallmarks of Alzheimer’s disease (AD) is the occurrence of neurofibrillary tangles (NFTs) that are composed of abnormally hyperphosphorylated microtubule-associated protein tau. Abnormal tau hyperphosphorylation is mainly induced due to the imbalance between protein kinases and phosphatases. In the tanglerich subregions of the hippocampus and parietal cortex in the brain of AD patients, the levels of the phosphorylationdependent protein peptidyl-prolyl cis-trans isomerase (Pin1) were found to be low. Although Pin1 can regulate tau phosphorylation, it is not clear whether the inhibition of glycogen synthase kinase 3 (GSK-3), the primary mediator of tau phosphorylation in AD, could reverse tau hyperphosphorylation induced due to the down-regulation of Pin1. We found that while suppression of Pin1, either by using its inhibitor Juglone or a shRNA plasmid against Pin1, induces tau hyperphosphorylation and GSK-3β activation both in vivo and in vitro, inhibition of GSK-3β by SB216763 or LiCl reverses tau hyperphosphorylation. Our data suggest that GSK-3β activation plays an important role in tau hyperphosphorylation induced by the down-regulation of Pin1, and the inhibition of GSK-3β might be a potential therapeutic approach for AD pathology.
Export Options
About this article
Cite this article as:
Xiong Yan-Si, Wang Dan-Li, Tan Lu, Wang Xiong, Chen Li-Ming, Gong Cheng-Xin, Wang Jian-Zhi and Zhu Ling-Qiang, Inhibition of Glycogen Synthase Kinase-3 Reverses Tau Hyperphosphorylation Induced by Pin1 Down-Regulation, CNS & Neurological Disorders - Drug Targets 2013; 12 (3) . https://dx.doi.org/10.2174/1871527311312030016
DOI https://dx.doi.org/10.2174/1871527311312030016 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Effects of Atorvastatin on Cerebral Blood Flow in Middle-Aged Adults at Risk for Alzheimer’s Disease: A Pilot Study
Current Alzheimer Research The Extra-Hematopoietic Role of Erythropoietin in Diabetes Mellitus
Current Diabetes Reviews Bone Marrow-Derived Mesenchymal Stem Cells Attenuate Amyloid β-Induced Memory Impairment and Apoptosis by Inhibiting Neuronal Cell Death
Current Alzheimer Research Histamine H3 Receptor (H3R) Antagonists and Inverse Agonists in the Treatment of Sleep Disorders
Current Pharmaceutical Design Impact of Tracer Retention Levels on Visual Analysis of Cerebral [<sup>18</sup>F]- Florbetaben Pet Images
Current Radiopharmaceuticals Melatonin as Antioxidant Under Pathological Processes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Serum Albumin Concentration and Cognitive Impairment
Current Alzheimer Research Subcellular Injuries in Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets Drug Transport Across the Blood-Brain Barrier and the Impact of Breast Cancer Resistance Protein (ABCG2)
Current Topics in Medicinal Chemistry Intravitreal Bevacizumab (Avastin®) for Diabetic Retinopathy at 24-months: The 2008 Juan Verdaguer-Planas Lecture
Current Diabetes Reviews Biomarker Research of Preclinical Alzheimer’s Disease and MCI Based on Neuroimage Techniques
Neuroscience and Biomedical Engineering (Discontinued) Therapeutic Role of Zonisamide in Neuropsychiatric Disorders
Mini-Reviews in Medicinal Chemistry Medical Treatment of Critical Limb Ischemia: Current State and Future Directions
Current Vascular Pharmacology State-of-the-Art Lentiviral Vectors for Research Use: Risk Assessment and Biosafety Recommendations
Current Gene Therapy Novel Therapeutic Targets in Neuropsychiatric Disorders: The Neuroepigenome
Current Pharmaceutical Design Currently Available Drugs for the Treatment of Obesity: Sibutramine and Orlistat
Mini-Reviews in Medicinal Chemistry Significance of High Levels of Endogenous Melatonin in Mammalian Cerebrospinal Fluid and in the Central Nervous System
Current Neuropharmacology Adiponectin and its Role in Cardiovascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets Targeting of α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia and the Use of Auditory Sensory Gating as a Translational Biomarker
Current Pharmaceutical Design Dynamics of Nicotinic Acetylcholine Receptors and Receptor-Associated Proteins at the Vertebrate Neuromuscular Junction
Current Alzheimer Research